↓ Skip to main content

RandomiSed clinical trial assessing Use of an anti-inflammatoRy aGent in attenUating peri-operatiVe inflAmmatioN in non-meTastatic colon cancer – the S.U.R.G.U.V.A.N.T. trial

Overview of attention for article published in BMC Cancer, August 2018
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#36 of 5,911)
  • High Attention Score compared to outputs of the same age (96th percentile)

Mentioned by

news
7 news outlets
blogs
2 blogs
twitter
3 tweeters

Citations

dimensions_citation
7 Dimensions

Readers on

mendeley
61 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
RandomiSed clinical trial assessing Use of an anti-inflammatoRy aGent in attenUating peri-operatiVe inflAmmatioN in non-meTastatic colon cancer – the S.U.R.G.U.V.A.N.T. trial
Published in
BMC Cancer, August 2018
DOI 10.1186/s12885-018-4641-x
Pubmed ID
Authors

H. Paul Redmond, Peter M. Neary, Marcel Jinih, Emer O’Connell, Niamh Foley, Rolf W. Pfirrmann, Jiang H. Wang, D. Peter O’Leary

Abstract

Peri-operative inflammation has been extensively highlighted in cancer patients as detrimental. Treatment strategies to improve survival for cancer patients through targeting peri-operative inflammation have yet to be devised. We conducted a multi-centre, randomised controlled clinical trial using Taurolidine in non-metastatic colon cancer patients. Patients were randomly assigned to receive Taurolidine or a placebo. The primary endpoint for the study was the mean difference in day 1 IL-6 levels. Secondary clinical endpoints included rates of post-operative infections and tumor recurrence. A total of 293 patients were screened for trial inclusion. Sixty patients were randomised. Twenty-eight patients were randomised to placebo and 32 patients to Taurolidine. IL-6 levels were equivalent on day 1 post-operatively in both groups. However, IL-6 levels were significantly attenuated over the 7 day study period in the Taurolidine group compared to placebo (p = 0.04). In addition, IL-6 levels were significantly lower at day 7 in the Taurolidine group (p = 0.04). There were 2 recurrences in the placebo group at 2 years and 1 in the Taurolidine group. The median time to recurrence was 19 months in the Placebo group and 38 months in the Taurolidine group (p = 0.27). Surgical site infection was reduced in the Taurolidine treated group (p = 0.09). Peri-operative use of Taurolidine significantly attenuated circulating IL-6 levels in the initial 7 day post-operative period in a safe manner. Future studies are required to establish the impact of IL-6 attenuation on survival outcomes in colon cancer. The trial was registered with EudraCT (year = 2008, registration number =  005570-12 ) and ISRCTN (year = 2008, registration number =  77,829,558 ).

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 61 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 61 100%

Demographic breakdown

Readers by professional status Count As %
Unspecified 12 20%
Student > Ph. D. Student 9 15%
Other 7 11%
Student > Master 5 8%
Lecturer 4 7%
Other 11 18%
Unknown 13 21%
Readers by discipline Count As %
Medicine and Dentistry 20 33%
Unspecified 12 20%
Nursing and Health Professions 6 10%
Biochemistry, Genetics and Molecular Biology 2 3%
Arts and Humanities 1 2%
Other 3 5%
Unknown 17 28%

Attention Score in Context

This research output has an Altmetric Attention Score of 66. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 September 2018.
All research outputs
#341,213
of 15,922,891 outputs
Outputs from BMC Cancer
#36
of 5,911 outputs
Outputs of similar age
#10,857
of 276,714 outputs
Outputs of similar age from BMC Cancer
#1
of 1 outputs
Altmetric has tracked 15,922,891 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 5,911 research outputs from this source. They receive a mean Attention Score of 4.1. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 276,714 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them